There is a mother I have known by sight since my child was in kindergarten.We had only ever exchanged greetings, but during a ...
Jordan Routch had never heard of Friedreich’s ataxia, but he’s running the Buffalo Creek half marathon to raise awareness ...
I developed a sleep disorder and autonomic ataxia last summer, took a six-month leave of absence, returned to work this March ...
Researchers have identified covert deletions of the proximal FXN gene that standard testing mistakes for identical repeat ...
Calendar of Events Support local nonprofits by attending one of these events and have fun for a good cause. For the latest ...
A monthly snapshot of FDA activity involving therapies used in the prevention, diagnosis, and treatment of neurologic conditions.
VIRGINIA BEACH, Va. — Steve Alexy walked carefully and pigeon-toed toward the dumbbells and mirror at the back of the gym, ...
We are thrilled to welcome Joerg to Oak Hill Bio at such an exciting time for our company,” said Josh Distler, Chief Executive Officer of Oak Hill Bio. “Joerg was an integral member of the team that ...
Overall, fluctuating symptom control was the most commonly cited reason for discontinuing a prior therapy, identified by 57% of providers, while preference for a consistent treatment schedule was the ...
Neurobiologist Wade Regehr has led research revolutionizing understanding of the outer layer of the cerebellum in the brain, ...
Cerebral palsy (CP) is the most common motor disability of childhood, a group of permanent movement disorders caused by a ...
Shionogi signaled its intent to focus on rare disease drugs in April when it acquired Radicava (edaravone), an amyotrophic lateral sclerosis (ALS) treatment, from Tanabe Pharma for $2.5 billion and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results